Stay updated with breaking news from Advaxis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
StockNews.com started coverage on shares of Advaxis (OTCMKTS:ADXS – Get Rating) in a research report report published on Friday morning. The firm issued a sell rating on the biotechnology company’s stock. ADXS stock opened at $0.11 on Friday. The firm has a 50 day moving average of $0.12 and a 200-day moving average of $0.28. […]
StockNews.com began coverage on shares of Advaxis (NASDAQ:ADXS – Get Rating) in a report issued on Monday. The firm set a “sell” rating on the stock. Shares of ADXS opened at $0.12 on Monday. Advaxis has a 52 week low of $0.08 and a 52 week high of $0.79. Advaxis Company Profile (Get Rating) Advaxis, […]
Advaxis Announces Agreement with Columbia University Irving Medical Center to Fund Phase 1 Study of ADXS-504 for the Treatment of Early Prostate Cancer Initiation of Phase 1 study in biochemically recurrent prostate cancer anticipated in Q2 April 05, 2021 08:00 ET | Source: Advaxis, Inc. Advaxis, Inc. Princeton, New Jersey, UNITED STATES PRINCETON, N.J., April 05, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, toda...